Guangdong Association of Clinical Trials
Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China
- Conditions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 150
- Registration Number
- NCT02381808
- Locations
- 🇨🇳
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 308
- Registration Number
- NCT02348450
- Locations
- 🇨🇳
WuHan Tongji Hospital, WuHan, Hubei, China
🇨🇳LiaoNing Provincial Tumor Hospital, Shenyang, Liaoning, China
🇨🇳The second affiliated hospital of zhejiang university school of medicine, Hangzhou, Zhejiang, China
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 54
- Registration Number
- NCT02171325
- Locations
- 🇨🇳
Jilin cancer hospital, Changchun, Jilin, China
Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients
- Conditions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 250
- Registration Number
- NCT02113852
Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 10
- Registration Number
- NCT02095782
- Locations
- 🇨🇳
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
A Prospective Epidemiologic Study of ALK-Positive NSCLC in China
- Conditions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 3649
- Registration Number
- NCT02042105
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Third-line Treatment of Gefitinib in NSCLC Patients
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 46
- Registration Number
- NCT01933347
- Locations
- 🇨🇳
Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China
Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC
- Conditions
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 180
- Registration Number
- NCT01740804
- Locations
- 🇨🇳
Guangdong general hospital, Guangzhou, Guangdong, China
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 176
- Registration Number
- NCT01724801
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 72
- Registration Number
- NCT01407822
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China